Welcome to our dedicated page for Cellebrite DI Ltd. SEC filings (Ticker: CLBT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Cellebrite DI Ltd. SEC filings document its foreign private issuer reporting for an AI-powered digital investigative and intelligence software business. Form 6-K current reports furnish quarterly and annual results releases, GAAP financial tables incorporated by reference into Form S-8 and Form F-3 registration statements, and annual general meeting voting results under the Israeli Companies Law and the company’s articles of association.
The filing record also includes Form 20-F annual reporting, which provides the recurring public-company framework for Cellebrite’s business, financial reporting and ordinary-share governance disclosures.
Cellebrite DI Ltd. Chief Financial Officer David Barter reported an open-market sale of 41,734 ordinary shares at a weighted average price of $16.3756 per share. The filing states the shares were originally granted as RSUs on July 7, 2025 and that the disposition is associated with tax obligations related to their vesting.
After the transaction, Barter directly holds 334,219 ordinary shares. The price reflects multiple trades between $16.21 and $16.62 per share.
Cellebrite DI Ltd. Chief Executive Officer Thomas E. Hogan reported an open-market sale of 103,188 ordinary shares. The shares were originally granted as restricted stock units on September 19, 2025, and the disposition is associated with tax obligations arising from the RSU vesting.
The shares were sold at a weighted average price of $15.7566 per share, in multiple trades between $15.44 and $15.97. Following this transaction, Hogan directly holds 590,777 ordinary shares of Cellebrite DI Ltd.
Company reported Form 144 notice showing proposed sales of common stock by an individual related party. The excerpt lists restricted stock vesting of 29,330 shares on 02/14/2024, and two reported dispositions in the past three months: 126,264 shares on 06/01/2026 and 43,983 shares on 07/01/2026.
Cellebrite DI Ltd. submitted a Rule 144 notice relating to Ordinary shares, par value NIS 0.00001, tied to vested Restricted Share Units under an issuer S-8 registered plan.
The filing lists 93,989 shares and references broker Morgan Stanley Smith Barney LLC; transaction dates shown include 07/07/2026 and 07/08/2026.
CLBT reports proposed sales of Common Stock under Form 144 by an affiliate and recent past disposals. The filing lists planned sales of 24,435 shares and 19,548 shares described as "Exercise of Options Under a Registered Plan" and shows 126,264 shares sold during the prior three months. Monetary figures appear in the excerpt as $677,342.60 and $2,000,968.74.
Cellebrite DI Ltd. filed a Rule 144 notice to sell 282,905 ordinary shares. The shares are described as Restricted Share Units vested under an issuer S-8 registered plan and the filing lists Morgan Stanley Smith Barney LLC as the broker. The filing shows dates 07/01/2026 and 07/02/2026.
CLBT submitted a Form 144 reporting a proposed sale of 126,264 shares of Common Stock with an aggregate value of $2,000,968.74, to be sold through Morgan Stanley Smith Barney LLC on 06/01/2026 on NASDAQ. The filing also lists two related option-exercise quantities of 60,606 and 65,658 shares dated 06/01/2026.
Cellebrite DI Ltd. Chief Marketing Officer David Nicholas Gee reported net open-market sales of 5,673 ordinary shares of Cellebrite (CLBT). The sales occurred on May 21, 2026 at weighted average prices of about $13.15 and $13.10 per share, within disclosed ranges of $13.00–$13.30 and $12.98–$13.32.
According to the footnotes, the shares sold were originally granted as restricted stock units on May 20, 2024, and the dispositions are associated with his tax obligations upon vesting. After these transactions, Gee directly holds 142,032 ordinary shares of Cellebrite. The filing states that the sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted by Gee on November 18, 2025, indicating they were scheduled in advance.
CLBT-related Form 144 filing reports planned resale and recent brokered sales of company common stock. The filing lists 3,064 Restricted Stock Units noted for sale on 05/20/2026. It also records recent 10b5-1 dispositions by David Gee: 228 shares on 05/12/2026, 2,609 shares on 02/23/2026, and 4,517 shares on 02/24/2026 with dollar amounts shown alongside each trade.
Cellebrite DI Ltd. submitted a Form 144 reporting proposed sales of Ordinary Shares by an insider. The form lists 5,673 Restricted Share Units vested under an S-8 plan (05/20/2026) and shows recent sales by David Gee: 2,609 shares on 02/23/2026, 4,517 shares on 02/24/2026 and 228 shares on 05/12/2026. The filing describes these transactions as employee compensation and restricted‑unit vesting.